ArticleJPGN reports2026
Early nutritional management of cystic fibrosis infants born with meconium ileus.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meconium ileus (MI) is a well-recognised neonatal presentation of cystic fibrosis (CF) and is associated with a high nutritional risk. While nutritional management principles are outlined in international guidelines, there is limited literature describing the practical experiences of nutritional management. The aim of this communication was to describe nutritional factors observed during the first year of life in a series of MI-CF infants. Data on nine surgically managed infants were reviewed from a UK CF centre. Timelines of (i) nutritional and surgical management and (ii) growth and intake outcomes are described. Findings highlight the heterogeneity of nutritional aspects in this group and the high prevalence of acute and chronic growth failure, further supporting the requirement for close nutritional monitoring. CFTR modulator therapies have revolutionised CF management and are increasingly available at younger ages. However, as treatment is initiated well after the neonatal period and acute MI, optimising nutritional management of MI-CF infants remains a priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.